BCL2 and acute myeloid leukemia: Venetoclax, a selective BCL-2 inhibitor, shows high response rates and durable remission, with a favorable safety profile, when used in combination with HMA or LDAC in AML patients who are ineligible for intensive chemotherapy [4,5,6].